Cullinan Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
CGEM$11.23-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Preferred Stock · Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · Noncontrolling · Total Stockholders' | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Loss | Deficit | Interests | Equity | |
| Balances at December 31, 2023 | 647,500 | $— | 42,900,083 | $4 | $654,685 | $(129) | $(200,857) | $192 | $453,895 |
| Net issuance of common stock under equity-based compensation plans | — | — | 165,562 | — | 1,085 | — | — | — | 1,085 |
| Equity-based compensation | — | — | — | — | 8,227 | — | — | — | 8,227 |
| Unrealized gain on investments | — | — | — | — | — | (202) | — | — | (202) |
| Net loss | — | — | — | — | — | — | (37,148) | (192) | (37,340) |
| Balances at March 31, 2024 | 647,500 | $— | 43,065,645 | $4 | $663,997 | $(331) | $(238,005) | $— | $425,665 |
| Preferred Stock · Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · Noncontrolling · Total Stockholders' | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Loss | Deficit | Interests | Equity | |
| Balances at December 31, 2022 | — | $— | 45,796,449 | $5 | $585,320 | $(2,601) | $(47,695) | $— | $535,029 |
| Contributions from noncontrolling interests | — | — | — | — | — | — | — | 179 | 179 |
| Issuance of preferred stock in exchange for common stock | 647,500 | — | (6,475,000) | (1) | 1 | — | — | — | — |
| Net issuance of common stock under equity-based compensation plans | — | — | 22,152 | — | (36) | — | — | — | (36) |
| Equity-based compensation | — | — | — | — | 7,259 | — | — | — | 7,259 |
| Unrealized gain on investments | — | — | — | — | — | 1,359 | — | — | 1,359 |
| Net loss | — | — | — | — | — | — | (57,962) | (179) | (58,141) |
| Balances at March 31, 2023 | 647,500 | $— | 39,343,601 | $4 | $592,544 | $(1,242) | $(105,657) | $— | $485,649 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.